Paliperidone - Generic Drug Details

What are the generic sources for paliperidone and what is the scope of patent protection?

Paliperidone is the generic ingredient in six branded drugs marketed by Janssen Pharms, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alembic, Amneal Pharms, Ascent Pharms Inc, Cspc Ouyi, Dr Reddys, Everest Lifesciences, Inventia, Lupin Ltd, Rk Pharma, Sun Pharm, Zydus Pharms, and Luye Innomind Pharma, and is included in seventeen NDAs. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are thirty-eight drug master file entries for paliperidone. Nineteen suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for paliperidone

US Patents:	8
Tradenames:	6
Applicants:	15
NDAs:	17
Drug Master File Entries:	38
Finished Product Suppliers / Packagers:	19
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	186
Patent Applications:	4,372
Drug Prices:	Drug price trends for paliperidone
What excipients (inactive ingredients) are in paliperidone?	paliperidone excipients list
DailyMed Link:	paliperidone at DailyMed

See drug prices for paliperidone

Recent Clinical Trials for paliperidone

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Province Nanjing Brain Hospital	PHASE4
US-Bangla Medical College Hospital	PHASE4
ACI Pharmaceuticals	PHASE4

See all paliperidone clinical trials

Generic filers with tentative approvals for PALIPERIDONE

Applicant	Application No.	Strength	Dosage Form
			SUSPENSION;EXTENDED RELEASE
		234MG/1.5ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
		156MG/ML	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for paliperidone

Drug Class

Atypical Antipsychotic

Anatomical Therapeutic Chemical (ATC) Classes for paliperidone

N05AX	Other antipsychotics
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

US Patents and Regulatory Information for paliperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajanta Pharma Ltd	PALIPERIDONE	paliperidone	TABLET, EXTENDED RELEASE;ORAL	218514-003	Jun 26, 2024		DISCN	No	No
Janssen Pharms	INVEGA HAFYERA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-006	Aug 30, 2021		RX	Yes	No	11,324,751
Janssen Pharms	INVEGA HAFYERA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-006	Aug 30, 2021		RX	Yes	No	11,304,951
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-003	Jul 26, 2024		RX	Yes	Yes	12,128,049
Alembic	PALIPERIDONE	paliperidone	TABLET, EXTENDED RELEASE;ORAL	218330-004	Sep 26, 2024	AB	RX	No	No
Amneal Pharms	PALIPERIDONE	paliperidone	TABLET, EXTENDED RELEASE;ORAL	204707-001	Sep 23, 2019	AB	RX	No	No
Janssen Pharms	INVEGA HAFYERA	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	207946-006	Aug 30, 2021		RX	Yes	No	12,208,100

Expired US Patents for paliperidone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVEGA	paliperidone	TABLET, EXTENDED RELEASE;ORAL	021999-006	Aug 26, 2008	5,158,952*PED
Janssen Pharms	INVEGA	paliperidone	TABLET, EXTENDED RELEASE;ORAL	021999-003	Dec 19, 2006	5,158,952*PED
Janssen Pharms	INVEGA	paliperidone	TABLET, EXTENDED RELEASE;ORAL	021999-004	Dec 19, 2006	5,158,952*PED
Janssen Pharms	INVEGA	paliperidone	TABLET, EXTENDED RELEASE;ORAL	021999-002	Dec 19, 2006	5,158,952*PED
Janssen Pharms	INVEGA	paliperidone	TABLET, EXTENDED RELEASE;ORAL	021999-001	Dec 19, 2006	5,158,952*PED

EU/EMA Drug Approvals for paliperidone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Byannli (previously Paliperidone Janssen-Cilag International)	paliperidone	EMEA/H/C/005486Byannli (previously Paliperidone Janssen-Cilag International) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.1).	Authorised	no	no	no	2020-06-18
Janssen-Cilag International NV	Trevicta (previously Paliperidone Janssen)	paliperidone	EMEA/H/C/004066Trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product.	Authorised	no	no	no	2014-12-05
Janssen-Cilag International N.V.	Xeplion	paliperidone	EMEA/H/C/002105Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.	Authorised	no	no	no	2011-03-04
Janssen-Cilag International NV	Invega	paliperidone	EMEA/H/C/000746Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.Invega is indicated for the treatment of schizoaffective disorder in adults.	Authorised	no	no	no	2007-06-24

Market Dynamics and Financial Trajectory for Paliperidone

Last updated: September 29, 2025

---

Introduction

Paliperidone, an atypical antipsychotic primarily prescribed for schizophrenia and schizoaffective disorder, has carved a significant niche within the neuropsychiatric medications landscape. As a metabolite of risperidone, paliperidone’s unique pharmacokinetics, regulatory approvals, and market positioning influence its commercial trajectory. Analyzing market dynamics and estimating financial outlooks require an examination of FDA approvals, competitive landscape, pricing strategies, and evolving healthcare policies.

---

Pharmacological Profile and Clinical Utility

Paliperidone operates as a dopamine D2 and serotonergic 5-HT2A receptor antagonist. Approved formulations include extended-release formulations like Invega Sustenna (monthly injections), Invega Trinza (quarterly injections), and oral variants such as Invega. These options provide flexible management of schizophrenia, contributing to patient adherence and treatment efficacy.

The drug’s tolerability profile, characterized by lower incidence of certain extrapyramidal symptoms, alongside its long-acting injectable formulations, demonstrates considerable value in treatment adherence—particularly in populations with historically poor compliance.

---

Market Dynamics

1. Regulatory Landscape and Approvals

Since its initial approval in 2006, paliperidone has enjoyed expanded approvals, notably:

• Long-acting injectable formulations: Invega Sustenna (2011), Invega Trinza (2015).
• Extended indications: Including schizoaffective disorder and maintenance therapy.

These approvals have cultivated a broad therapeutic niche, especially in jurisdictions with robust mental health treatment infrastructure.

2. Competitive Landscape

Paliperidone faces competition from other atypical antipsychotics, including risperidone, olanzapine, aripiprazole, and newer agents such as brexpiprazole and lumateperone. Its long-acting formulations specifically target adherence challenges—a key differentiator but also a market with aggressive brand competition.

3. Pricing and Reimbursement

Premium pricing strategies underpin the revenue model for long-acting formulations. For instance, in the US, the annual cost for Invega Trinza can surpass $30,000 per patient (depending on payer arrangements) [2]. Insurance coverage and restrictions influence market penetration and usage rates.

4. Prescriber and Patient Adoption

Physician familiarity, patient preferences, and healthcare provider incentives shape prescribing behaviors. Increasing awareness of the benefits of long-acting injectables improves adoption, especially in health systems emphasizing medication adherence to reduce hospitalization rates.

5. Global Market Penetration

While North America and Europe constitute dominant markets due to high prevalence and regulatory approvals, emerging markets such as Asia-Pacific present growth opportunities, facilitated by increasing diagnosis rates and evolving healthcare infrastructure.

---

Financial Trajectory

1. Revenue Trends

Post-launch, paliperidone product sales have generally followed an upward trajectory, driven by expanding indications and formulations. The global antipsychotic market surpassed $14 billion in 2022 with a compounded annual growth rate (CAGR) of approximately 4% [3]. Paliperidone's sustained share stems from its portfolio of long-acting injectable products.

2. Revenue Drivers

Major revenue streams are attributed to:

• Invega Sustenna/Trinza: Long-acting injectables with high adherence benefits.
• Oral formulations: Often used as initiation before long-acting injections.

3. Market Challenges

Pricing pressures and biosimilar or generic risperidone availability exert downward pressure. Patent expiry risks, though currently limited due to formulation-specific patents, remain a concern for future pipeline stabilization.

4. R&D and Pipeline Potential

Pipeline development includes novel delivery mechanisms and combination therapies, potentially broadening the market. Companies are exploring injectables with extended durations, which could further increase adherence and compliance.

5. Strategic Collaborations and Market Expansion

Partnerships with healthcare providers and government health agencies facilitate broader access. Market expansion into emerging economies, coupled with targeted marketing, can augment revenues.

---

Regulatory and Policy Influences

Regulatory frameworks and healthcare policies heavily influence the financial outlook. Favorable reimbursement policies and inclusion in treatment guidelines promote adoption, especially in healthcare systems emphasizing chronic disease management.

Conversely, cost containment initiatives and increased scrutiny on drug pricing may dampen revenue growth margins in certain markets.

---

Future Outlook and Market Potential

Based on current trends, revenues for paliperidone formulations are projected to grow at a CAGR of 3-5% over the next five years, contingent on:

• Continued adoption of long-acting injectables.
• Expansion into new markets and indications, including off-label uses in certain neuropsychiatric conditions.
• Next-generation formulations with improved efficacy and safety profiles.
• Potential biosimilar threats post-patent expiration, which may impact pricing and market share.

The global mental health burden, increasing awareness, and innovations in delivery systems are favorable for sustained growth but must be balanced against pricing pressures and regulatory hurdles.

---

Key Takeaways

• Market Positioning: Paliperidone's long-acting injectable formulations enhance adherence, affording it a strategic edge in the antipsychotic market.
• Revenue Drivers: Premium pricing, expanded formulations, and increasing adoption in developed markets underpin revenue growth.
• Competitive Challenges: Biosimilars and generics, alongside intense competition, threaten future margins.
• Growth Opportunities: Market expansion in emerging economies and pipeline innovations could sustain long-term growth.
• Regulatory Impact: Favorable reimbursement policies bolster market penetration; policy shifts can lead to volatility.

---

FAQs

1. What factors influence the pricing strategy of paliperidone formulations?
Pricing depends on formulation type, manufacturing costs, competitive landscape, reimbursement policies, and perceived value regarding adherence and clinical benefits.

2. How does patent expiration affect paliperidone’s market outlook?
Patent expirations could enable biosimilar entry, leading to competitive price reductions and potential revenue erosion unless countered by next-generation formulations or indication expansions.

3. What are the primary competitors to paliperidone?
Main competitors include orally administered atypical antipsychotics like aripiprazole and olanzapine, as well as other long-acting injectables such as risperidone microspheres (Risperdal Consta) and newer agents like brexpiprazole.

4. How do healthcare policies impact the adoption of paliperidone?
Policies favoring medication adherence, mental health funding, and reimbursement schemes significantly influence prescribing patterns and market penetration.

5. What future innovations could alter paliperidone’s market position?
Development of longer-acting formulations, personalized medicine approaches, and combination therapies could redefine treatment paradigms and expand market share.

---

References

1. DrugBank: Profile of Paliperidone.
2. IQVIA, “US Prescription Drug Expenditure Data,” 2022.
3. Grand View Research, “Antipsychotic Drugs Market Size & Trends,” 2022.